Diabetic nephropathy is the most common cause of end-stage renal disease (ESRD), and the proportion of patients with ESRD who have diabetes (most of whom have T2DM) has increased over the past ...
Diabetic nephropathy is the leading cause of kidney disease in patients starting renal replacement therapy and affects ~40% of type 1 and type 2 diabetic patients. It increases the risk of death ...
R3R-01 is under development for the treatment of Alport syndrome, diabetic kidney disease and focal segmental glomerulosclerosis. It is administered through oral route.
Diabetes mellitus affects in excess of 285 million people worldwide and this number is predicted to increase to 439 million by 2030. A major complication of diabetes is kidney disease termed diabetic ...
Open label study designed to evaluate the safety, tolerability, and efficacy of bremelanotide in patients with Type 2 diabetic nephropathy Demonstrated efficacy at 6 months 71% percent of patients ...